Clinical Application of A New <i>In Vitro</i> High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients

WU Haibing; ZHAO Xiaoyan; SHEN Mingfang; Huang Rui; CHEN Cheng; REN Tao; SHEN Yang

doi:10.3971/j.issn.1000-8578.2020.19.1364

Cancer Research on Prevention and Treatment > 2020 > 47(6): 462-465. > DOI: 10.3971/j.issn.1000-8578.2020.19.1364

WU Haibing, ZHAO Xiaoyan, SHEN Mingfang, Huang Rui, CHEN Cheng, REN Tao, SHEN Yang. Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 462-465. DOI: 10.3971/j.issn.1000-8578.2020.19.1364

Citation:

PDF (4580 KB)

Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients

1.
Department of Hematology, The First Hospital of Jiaxing, Jiaxing 314050, China
2.
Hefei Institute of Material Science, Chinese Academy of Sciences, Hefei 230088, China

More Information

Corresponding author:
SHEN Yang, E-mail:13905737152@163.com
Received Date: October 31, 2019
Revised Date: March 15, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To explore the clinical value of new high-throughput drug sensitivity (HDS) screening technology in the individualized medication of relapsed refractory acute myeloid leukemia patients.
Methods
We collected bone marrow samples of 19 patients with relapsed and refractory acute myeloid leukemia, enriching and culturing leukemic cancer cells by HDS technology. In vitro efficacy evaluation of 15 single drugs and 17 chemotherapy regimens was carried out according to the blood peak concentration corresponding to clinical dose. The drugs and programs were divided into four levels: high, medium, low and insensitive, according to the inhibition rate of cell activity detected and calculated by Celltiter-Glo based chemiluminescence, then we observed the clinical remission rate.
Results
Among the 19 patients, there were 4 cases of non-remission (NR), 4 cases of complete remission (CR) and 11cases of partial remission (PR), and the overall remission rate was 78.94%. The sensitivity frequency of DAE, DAC, HAD and HD-DA schemes were higher than 68%.
Conclusion
The high-throughput drug sensitivity screening technology is a rapid, efficient and low-cost detection technology, with good clinical application value in individualized medication of relapsed refractory AML patients, worthy of clinical promotion in the post genomic era.
- Drug sensitivity,
- AML,
- High-throughput,
- HDS

FullText(HTML)

References (16)

References

[1]	Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells[J]. Nature, 2012, 483(7391): 570-575. doi: 10.1038/nature11005
[2]	Pemovska T, Kontro M, Yadav B, et al. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia[J]. Cancer Discov, 2013, 3(12): 1416-1429. doi: 10.1158/2159-8290.CD-13-0350
[3]	Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer[J]. Science, 2014, 346(6216): 1480-1486. doi: 10.1126/science.1254721
[4]	Chia S, Low JL, Zhang X, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time[J]. Nat Commun, 2017, 8(1): 435. doi: 10.1038/s41467-017-00451-5
[5]	Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia[J]. Nature, 2018, 562(7728): 526-531. doi: 10.1038/s41586-018-0623-z
[6]	Pemovska T, Kontro M, Yadav B, Edgren H, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia[J]. Cancer Discov, 2013, 3(12): 1416-1429. doi: 10.1158/2159-8290.CD-13-0350
[7]	Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia[J]. J Clin Oncol, 2004, 22(16): 3432-3433. doi: 10.1200/JCO.2004.99.116
[8]	Marquart J, Chen EY, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology[J]. JAMA Oncol, 2018, 4(8): 1093-1098. doi: 10.1001/jamaoncol.2018.1660
[9]	Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261. doi: 10.1038/s41586-019-0987-8
[10]	Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics[J]. Nat Rev Cancer, 2015, 15(12): 747-756. doi: 10.1038/nrc4015
[11]	Yan X, Zhou L, Wu Z, et al. High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing[J]. Biomaterials, 2019, 198: 167-179. doi: 10.1016/j.biomaterials.2018.05.020
[12]	朱路, 勾越阳, 鄢晓君, 等.基于病人自体肿瘤细胞体外培养模型的个体化精准用药[J].中国医疗设备, 2016, 31(6): 13-18, 35. doi: 10.3969/j.issn.1674-1633.2016.06.003 Zhu L, Gou YY, Yan XJ, et al. Precise medicine in cancer treatmentvia patient derivedin vitro tumor model[J]. Zhongguo Yi Liao She Bei, 2016, 31(6): 13-18, 35. doi: 10.3969/j.issn.1674-1633.2016.06.003
[13]	刘飞扬, 黄瑞, 任涛, 等.肿瘤精准用药治疗的技术体系[J].高科技与产业化, 2016, 242: 50-52. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gkjycyh201607007 Liu FY, Huang R, Ren T, et al. Technology system of cancer Precision medicine[J]. Gao Ke Ji Yu Chan Ye Hua, 2016, 242: 50-52. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gkjycyh201607007
[14]	Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells[J]. Am J Pathol, 2012, 180(2): 599-607. doi: 10.1016/j.ajpath.2011.10.036
[15]	Almosailleakh M, Schwaller J. Murine Models of Acute Myeloid Leukaemia[J]. Int J Mol Sci, 2019, 20(2). pii: E453. doi: 10.3390/ijms20020453
[16]	Mazzocchi AR, Rajan SAP, Votanopoulos KI, et al. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening[J]. Sci Rep, 2018, 8(1): 2886. doi: 10.1038/s41598-018-21200-8

[1]	MIAO Wenyan, LIN Siying, XU Jianli, WANG Hongbo, JIANG Ming. Effects of Peripheral Blood Stem Cell Transplantation from Haploidentical Versus Matched Sibling Donors on High-risk and Refractory/Relapsed Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2023, 50(10): 988-993. DOI: 10.3971/j.issn.1000-8578.2023.23.0282
[2]	JI Xiaojun, ZHAO Tingli, MIAO Lei, SI Yaxuan, WU Jian, XU Dan. Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 413-421. DOI: 10.3971/j.issn.1000-8578.2023.22.1056
[3]	LIAO Jun, KONG Peiyan. Research Progress of Relationship Between Urokinase Plasminogen Activator System and Acute Myelocytic Leukemia[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 305-308. DOI: 10.3971/j.issn.1000-8578.2016.04.014
[4]	MA Yingying, KONG Peiyan. Targeted Therapy with Sorafenib for FLT3-ITD-positive Acute Myeloid Leukemia Patients[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 938-941. DOI: 10.3971/j.issn.1000-8578.2015.09.017
[5]	YANG Jie, CHEN Hong. Expression of HOX11 Gene in Acute Myeloid Leukemia Patients and Its Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 478-480. DOI: 10.3971/j.issn.1000-8578.2015.05.012
[6]	ZHANG Xi, CHANG Chunkang, ZHAO Youshan, GUO Juan, FEI Chengming, LI Xiao. Clinical Comparative Observation of HIA and IA Regimen in Initial Treatment of Newly Diagnosed Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2013, 40(06): 541-546. DOI: 10.3971/j.issn.1000-8578.2013.06.009
[7]	YANG Lin, LUO Jian-min, WEN Shu-peng, LIU Xiao-jun, DU Xing-yan, ZHANG Jing-yu, YAO Li, DONG Zuo-ren. Expressions of SHP-1 and JAKs Genes in AML Patients and Their Correlation[J]. Cancer Research on Prevention and Treatment, 2009, 36(12): 1031-1034. DOI: 10.3971/j.issn.1000-8578.2009.12.011
[8]	LONG Yi, DU Xin, WENG Jian yu, LIN Wei. Effect of Arsenic Trioxide on Fas/FasL in Human Non-M3 AML and ALL Cell Lines[J]. Cancer Research on Prevention and Treatment, 2004, 31(06): 336-337. DOI: 10.3971/j.issn.1000-8578.893
[9]	FEI Jia, ZHANG Yuan. Study of VEGF Antisense Oligodeoxynudeotide and Daunorubicin to Increase the Sensitivity of AML and CML Cells[J]. Cancer Research on Prevention and Treatment, 2004, 31(06): 326-329. DOI: 10.3971/j.issn.1000-8578.894
[10]	Wang Wenjing, Cao Huiping, Jing Fengxiang. The Result Based on the Drug Sensitive Test of Tumor Cell Directed to Treat the 40 Acute Leukemia[J]. Cancer Research on Prevention and Treatment, 1999, 26(3): 203-204.

Cited By

Cited by

Periodical cited type(4)

1.	张辉，严匡华. 环孢素结合CAG化疗对难治性急性髓细胞白血病的治疗效果及安全性分析. 黑龙江医学. 2024(10): 1174-1176 .
2.	祁文静，徐学聚，李白，王叨，盛光耀，朱平，王春美. 高通量药敏检测技术在儿童复发难治性急性白血病中的应用. 中国当代儿科杂志. 2024(10): 1093-1100 .
3.	林丹娜，张观梅，刘改英，金明，张亚芥，吴莉，程明，余莉华，杨丽华. 高通量药物敏感性检测在儿童复发难治性急性白血病的应用. 中国小儿血液与肿瘤杂志. 2023(01): 16-20 .
4.	王海峰，曲颜丽. 高通量体外药敏实验在晚期胃癌个体化用药中的意义. 中华实验外科杂志. 2022(12): 2453-2456 .

Other cited types(1)

Get Citation

PDF

XML

Article views (1722) PDF downloads (398) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients